Pharmaceuticals Global On demand · 24-48h

Global Steroid Hormone API Market Strategic Research Report

Global Steroid Hormone API Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Steroid Hormone API Market
$2.95B2025
5.9%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Prednisone Series, Dexamethasone Series, Betamethasone Series, Hydrocortisone Series, Sex Hormones Series, Other

By Application: Injectable Drugs, Oral Drugs, Topical Drugs, Inhaled Drugs

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Pfizer CentreOne, EUROAPI, GlaxoSmithKline, TAPI, Hovione, Axplora, Steroid SpA, Avik Pharmaceutical, Anuh Pharma, Symbiotec Pharmalab, Sun Pharmaceutical, Cipla, Wellona Pharma, Tianjin Tianyao Pharmaceuticals, Zhejiang Xianju Pharmaceutical, Zhejiang Xianju Xianle Pharmaceutical, Tianjin Pacific Pharmaceutical, Shandong Xinhua Pharmaceutica Group, Jiangsu Lianhuan Pharmaceutical, Shanghai New Hualian Pharmaceutical, Shandong Taihua Biotech, Saituo Biological Technology, Zhejiang Xianju Junye Pharmaceutical, Tianjin Jinhui Pharmaceutical Group, Tianjin Xinyi Jinjin Pharmaceutical, Xi'an Guokang Ruijin Pharmaceutical

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 175 pages
Market size 2025
$2.95B
Billion USD
Forecast CAGR
5.9%
2025-2032
Forecast 2032
$4.4B
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

نظرة عامة

Scope of the Report

The global Steroid Hormone API market size is predicted to grow from US$ 2,950 million in 2025 to US$ 4,378 million in 2032; it is expected to grow at a CAGR of 5.9% from 2026 to 2032.

Steroid Hormone APIs are active pharmaceutical ingredients based on the steroid backbone, encompassing subcategories such as sex hormones (e.g., estrogen, progesterone, testosterone) and adrenal corticosteroids (glucocorticoids, mineralocorticoids). They are widely used clinically for endocrine regulation, anti-inflammatory and immunosuppressive therapy, contraception, and hormone replacement therapy. Steroid hormone APIs are typically supplied in raw material form for the production of oral, injectable, and topical formulations, serving as essential building blocks in modern pharmaceuticals and biopharmaceuticals. In 2024, the global average price of Steroid Hormone APIs was USD 593 per kilogram, with a total sales volume of 4,794 tons.

The Steroid Hormone API market has experienced steady growth in recent years, driven largely by global clinical demand for corticosteroids and sex hormone drugs. These APIs are widely applied in therapies such as anti-inflammatory, immunosuppressive, endocrine regulation, hormone replacement, and anti-allergic treatments, covering injectable, oral, and topical formulations. The global market is dominated by a few multinational pharmaceutical companies, including Pfizer, EUROAPI, and GlaxoSmithKline, while Chinese manufacturers hold advantages in medium- to low-end steroidal API production and dominate the supply of initial and intermediate products, providing a stable source of raw materials for the global market.Looking ahead, the Steroid Hormone API market is expected to shift toward high-end, technology-intensive products, particularly for advanced corticosteroid derivatives with enhanced efficacy, safety, and multifunctionality. The adoption of automated, continuous, and green manufacturing technologies will improve production efficiency and product quality. Furthermore, the rise of personalized medicine and precision therapies will drive demand for customized, high-value steroidal APIs. China's advantages in raw material supply and production technology are likely to attract more multinational production and R&D activities, accelerating industrial upgrading and global market integration.Key drivers include sustained clinical demand for anti-inflammatory, immunomodulatory, and hormone replacement therapies, the aging population and increasing chronic disease prevalence, and China's competitive edge in raw materials, production cost, and integrated supply chains. Technological innovation and supportive policies also bolster market expansion. However, challenges remain, such as the high R&D barrier for advanced steroidal APIs, stringent international quality and certification requirements, complex production processes with strict regulatory oversight, as well as raw material price volatility and environmental pressures. These factors collectively pose challenges for companies in R&D capability, production efficiency, and global market positioning.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Steroid Hormone API market?

What factors are driving Steroid Hormone API market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Steroid Hormone API market opportunities vary by end market size?

How does Steroid Hormone API break out by Type, by Application?

This report presents a comprehensive overview of the global Steroid Hormone API market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Prednisone Series
  • Dexamethasone Series
  • Betamethasone Series
  • Hydrocortisone Series
  • Sex Hormones Series
  • Other

Segment by Application

  • Injectable Drugs
  • Oral Drugs
  • Topical Drugs
  • Inhaled Drugs

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Steroid Hormone API market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Injectable Drugs, Oral Drugs, Topical Drugs evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Steroid Hormone API Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 5.9%
Regional growth momentum
Market share by segment
Key metrics
Base value
$2.95B
2025
Forecast
$4.4B
2032
CAGR
5.9%
2025–2032
Regions
5
global
Key companies
Pfizer CentreOneEUROAPIGlaxoSmithKlineTAPIHovioneAxploraSteroid SpAAvik Pharmaceutical
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Prednisone SeriesDexamethasone SeriesBetamethasone SeriesHydrocortisone SeriesSex Hormones SeriesOther
By Application
Injectable DrugsOral DrugsTopical DrugsInhaled Drugs

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Prednisone Series
  • 3.1.3 Dexamethasone Series
  • 3.1.4 Betamethasone Series
  • 3.1.5 Hydrocortisone Series
  • 3.1.6 Sex Hormones Series
  • 3.1.7 Other
  • 3.1.8 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Injectable Drugs
  • 4.1.3 Oral Drugs
  • 4.1.4 Topical Drugs
  • 4.1.5 Inhaled Drugs
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Pfizer CentreOne
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 EUROAPI
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 GlaxoSmithKline
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 TAPI
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Hovione
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Axplora
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Steroid SpA
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Avik Pharmaceutical
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Anuh Pharma
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Symbiotec Pharmalab
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Sun Pharmaceutical
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Cipla
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Wellona Pharma
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Tianjin Tianyao Pharmaceuticals
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Zhejiang Xianju Pharmaceutical
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Zhejiang Xianju Xianle Pharmaceutical
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Tianjin Pacific Pharmaceutical
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Shandong Xinhua Pharmaceutica Group
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Jiangsu Lianhuan Pharmaceutical
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Shanghai New Hualian Pharmaceutical
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 Shandong Taihua Biotech
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 Saituo Biological Technology
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
  • 8.23 Zhejiang Xianju Junye Pharmaceutical
  • 8.23.1 Company Overview
  • 8.23.2 Key Products & Segments
  • 8.23.3 Financial Performance (2023–2025)
  • 8.23.4 Business Strategy
  • 8.23.5 SWOT Analysis
  • 8.23.6 Strategic Implications (2026–2032)
  • 8.24 Tianjin Jinhui Pharmaceutical Group
  • 8.24.1 Company Overview
  • 8.24.2 Key Products & Segments
  • 8.24.3 Financial Performance (2023–2025)
  • 8.24.4 Business Strategy
  • 8.24.5 SWOT Analysis
  • 8.24.6 Strategic Implications (2026–2032)
  • 8.25 Tianjin Xinyi Jinjin Pharmaceutical
  • 8.25.1 Company Overview
  • 8.25.2 Key Products & Segments
  • 8.25.3 Financial Performance (2023–2025)
  • 8.25.4 Business Strategy
  • 8.25.5 SWOT Analysis
  • 8.25.6 Strategic Implications (2026–2032)
  • 8.26 Xi'an Guokang Ruijin Pharmaceutical
  • 8.26.1 Company Overview
  • 8.26.2 Key Products & Segments
  • 8.26.3 Financial Performance (2023–2025)
  • 8.26.4 Business Strategy
  • 8.26.5 SWOT Analysis
  • 8.26.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Steroid Hormone API market?
The global Steroid Hormone API market is estimated at US$ 2.95 billion in 2025 (base year) and is projected to reach US$ 4.38 billion by 2032.
What is the forecast CAGR for the Steroid Hormone API market?
The market is expected to grow at a CAGR of 5.9% from 2026 to 2032, expanding from US$ 2.95 billion in 2025 to US$ 4.38 billion in 2032, roughly 1.5 times its base-year value.
What is Steroid Hormone API?
Steroid Hormone APIs are active pharmaceutical ingredients based on the steroid backbone, encompassing subcategories such as sex hormones (e.g., estrogen, progesterone, testosterone) and adrenal corticosteroids (glucocorticoids, mineralocorticoids). They are widely used clinically for endocrine regulation, anti-inflammatory and immunosuppressive therapy, contraception, and hormone replacement therapy.
What are the main segments of the Steroid Hormone API market by type?
By type, the market is segmented into Prednisone Series, Dexamethasone Series, Betamethasone Series, Hydrocortisone Series, Sex Hormones Series and Other.
Which applications drive demand in the Steroid Hormone API market?
Key applications covered include Injectable Drugs, Oral Drugs, Topical Drugs and Inhaled Drugs.
Who are the key players in the Steroid Hormone API market?
Key players profiled include Pfizer CentreOne, EUROAPI, GlaxoSmithKline, TAPI, Hovione, Axplora, Steroid SpA and Avik Pharmaceutical, among 26 companies covered in total.
Which regions and countries are covered for Steroid Hormone API?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Steroid Hormone API market?
The Steroid Hormone API market has experienced steady growth in recent years, driven largely by global clinical demand for corticosteroids and sex hormone drugs.
What challenges does the Steroid Hormone API market face?
However, challenges remain, such as the high R&D barrier for advanced steroidal APIs, stringent international quality and certification requirements, complex production processes with strict regulatory oversight, as well as raw material price volatility and environmental pressures.
Who should buy the Steroid Hormone API market report?
The report is intended for manufacturers and solution providers, distributors and end users in Injectable Drugs, Oral Drugs and Topical Drugs, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Steroid Hormone API market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from ‏3,500.00 US$
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.